Kos Biotechnology Partners is a global investment firm that focuses exclusively on innovative therapeutics under development by the biotechnology and pharmaceutical sectors. Kos was founded in 2024 with the goal of becoming a premier life sciences-focused investment firm, providing superior returns and minimizing the risks inherent in the sector, while investing in tomorrow’s therapeutic breakthroughs, under development by both private and public biopharmaceutical companies across all stages of development.
Dr. Simos Simeonidis, is a biotechnology industry expert with 30 years’ experience, who trained as an academic scientist, before transitioning to the industry and investment side of science. Prior to founding Kos, Dr. Simeonidis was Managing Partner, co-CEO and co-CIO of Ally Bridge Group, a $2B global life sciences investment firm, where he invested in both private and public companies across therapeutic areas, modalities and stages of development, and managed ~30 employees worldwide. Before joining Ally Bridge Group, he was Partner, Senior Managing Director and co-Head of Investment Research at Sarissa Capital Management, a $1.5B biopharma-focused, activist investment firm, founded by Dr. Alex Denner, Carl Icahn’s former head of healthcare investments. During his time at Sarissa Capital, Dr. Simeonidis invested across therapeutic areas and modalities, in both private and public biopharmaceutical companies, ranging from early stage biotechs to large cap pharma.
Dr. Simeonidis joined Sarissa Capital from the Royal Bank of Canada (RBC), where he was Managing Director and Senior Biotechnology Analyst. He had spent more than a decade as a biotechnology analyst covering hundreds of public and private companies across all therapeutic areas at a number of investment banks, including Cowen & Co. and Morgan Stanley. Before transitioning to Wall Street, he held roles in Global Commercial Strategy and Business Development in the biopharmaceutical industry at Johnson & Johnson, GlaxoSmithKline and Novartis.
Dr. Simeonidis was born and raised in Athens, Greece, moved to the US to attend college, received his B.S. in Biology from Loyola University Chicago, and then spent a decade training in Genetics and Molecular Biology, first in the Department of Genetics at the University of Chicago, and then in the Department of Biochemistry & Molecular Biophysics at Columbia’s College of Physicians and Surgeons in New York, where he studied transcriptional regulation via the NF-kB/IkB pathway and cloned the mouse IkB epsilon gene. After receiving his M.A., M.Phil. and Ph.D. from Columbia, he completed his Postdoctoral Fellowship at Harvard Medical School and the Brigham & Women’s Hospital in the Department of Pathology and the laboratory of Professor Tucker Collins, before being appointed to the Faculty at Harvard Medical School and the Beth Israel Deaconess Medical Center.
During his time as a faculty member at Harvard Medical School, his basic science research on the regulation of gene expression exposed him to the drug development and the finance aspects of basic biomedical research, which at the time were generating a lot of excitement in both the scientific world and the financial markets, following the discoveries that came out of the Human Genome Project. Intrigued by the potential of combining deep scientific knowledge with understanding the world of biotechnology drug development and finance, he attended the University of Pennsylvania’s Wharton School of Business, graduating with a Master of Business Administration degree with a major in Healthcare Management.
In addition to his investment career, Dr. Simeonidis has served on the Board of Directors of several private and public companies, including Regulus Therapeutics, Sarissa Capital Acquisition Corporation, Shoreline Biosciences, and Delsona Therapeutics, a Focused Ultrasound therapeutics company he co-founded, spun out of Columbia Medical School and serves as interim CEO and Chairman of the Board.
Dr. Simeonidis is active in a number of charitable causes, including as a Member of Fondation Sante, a private organization that provides funding to support biomedical innovation efforts in Greece.
BS Loyola University Chicago
MA, MPhil, PhD Columbia College of Physicians & Surgeons
Postdoctoral Fellowship Harvard Medical School
MBA University of Pennsylvania Wharton School of Business
Copyright © 2024 Kos Biotechnology Partners - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.